| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.41 |
| 52 Week High | CN¥11.98 |
| 52 Week Low | CN¥5.78 |
| Beta | 0.31 |
| 11 Month Change | 2.23% |
| 3 Month Change | -22.30% |
| 1 Year Change | -44.79% |
| 33 Year Change | -34.92% |
| 5 Year Change | -21.37% |
| Change since IPO | 8.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603811 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.5% | 0.05% | -1.6% |
| 1Y | -44.8% | -11.8% | -19.6% |
Return vs Industry: 603811 underperformed the CN Pharmaceuticals industry which returned -11.8% over the past year.
Return vs Market: 603811 underperformed the CN Market which returned -19.6% over the past year.
Price Volatility
| 603811 volatility | |
|---|---|
| 603811 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 603811's share price has been volatile over the past 3 months.
Volatility Over Time: 603811's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | 738 | Chunjian Zhao | www.chengyipharma.com |
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. produces and sells APIs, injections, capsules, tablets, pharmaceutical intermediates in China. The company was formerly known as Wenzhou No. 3 Pharmaceutical Factory and changed its name to Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. Fundamentals Summary
| 603811 fundamental statistics | |
|---|---|
| Market cap | CN¥2.10b |
| Earnings (TTM) | CN¥155.83m |
| Revenue (TTM) | CN¥676.85m |
13.5x
P/E Ratio3.1x
P/S RatioIs 603811 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603811 income statement (TTM) | |
|---|---|
| Revenue | CN¥676.85m |
| Cost of Revenue | CN¥241.68m |
| Gross Profit | CN¥435.18m |
| Other Expenses | CN¥279.35m |
| Earnings | CN¥155.83m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 21, 2024
| Earnings per share (EPS) | 0.48 |
| Gross Margin | 64.29% |
| Net Profit Margin | 23.02% |
| Debt/Equity Ratio | 34.9% |
How did 603811 perform over the long term?
See historical performance and comparison